<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04717115</url>
  </required_header>
  <id_info>
    <org_study_id>JR_Lufu_PCD_01_2020-1</org_study_id>
    <nct_id>NCT04717115</nct_id>
  </id_info>
  <brief_title>Genotype/Phenotype Correlation With Focus on Lung Function in Primary Ciliary Dyskinesia (PCD)</brief_title>
  <acronym>LuFu_PCD</acronym>
  <official_title>An International Study on Genotype/Phenotype Correlation With Focus on Lung Function in Patients With Primary Ciliary Dyskinesia (PCD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NOVA Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Geneva, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruhr University of Bochum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal Brompton &amp; Harefield NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leicester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bambino Gesù Hospital and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nicosia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Niños R. Gutierrez de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Marmara University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Motol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Children's Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leeds Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schneider Children's Medical Center, Israel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Belgrade</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Martin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abderrahmane Mami Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder characterized by dysfunction of&#xD;
      motile cilia associated with recurrent infections of the airways, laterality defects (Situs&#xD;
      inversus totalis in about 50% of cases) and fertility problems. At present, mutations in &gt; 45&#xD;
      genes associated with PCD and mucociliary clearance disorders have been identified,&#xD;
      representing most likely two thirds of all human cases.&#xD;
&#xD;
      Aim of this study are:&#xD;
&#xD;
        -  Correlation between genotype and lung function of patients with genetically confirmed&#xD;
           PCD in an international cohort on a longitudinal basis&#xD;
&#xD;
        -  Determination of further parameters, such as body mass index (BMI), possibly associated&#xD;
           with lung function in genetically confirmed PCD patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background Primary Ciliary Dyskinesia (PCD) is a rare genetic disorder characterized by&#xD;
      dysfunction of motile cilia associated with recurrent infections of the airways, laterality&#xD;
      defects (Situs inversus totalis in about 50% of cases) and fertility problems. At present,&#xD;
      mutations in &gt; 40 genes associated with PCD and mucociliary clearance disorders have been&#xD;
      identified, representing most likely two thirds of all human cases. While being involved in&#xD;
      the majority of identified PCD genes, our working group has a great expertise in genetic&#xD;
      analysis and diagnostic work-up of patients with PCD.&#xD;
&#xD;
      Hallmark symptom of PCD is the chronic purulent lung disease due to the reduced mucociliary&#xD;
      clearance. Chronic inflammation and recurrent infections of the airways promote continuous&#xD;
      lung damage, bronchiectasis and could finally lead to total lung failure. For other&#xD;
      congenital diseases with chronic lung conditions, e.g. cystic fibrosis (CF), an affected lung&#xD;
      function with a steady decline is well described and spirometry is widely used to monitor&#xD;
      disease progression. For PCD there are only limited data available and studies often comprise&#xD;
      small cohorts. In general, available data assume a decline of lung function in PCD patients&#xD;
      compared to healthy individuals, but less pronounced than in CF. Altogether, results of the&#xD;
      studies remain heterogeneous, in particular concerning the influence of an early diagnosis&#xD;
      and a proper treatment on lung function.&#xD;
&#xD;
      Furthermore, despite a significant progression in genetically solved cases there are almost&#xD;
      no data on genotype specific lung function in patients with PCD. Recently, there are few&#xD;
      studies indicating an association between specific ultrastructural or genetic defects, e.g.&#xD;
      patients carrying mutations in the genes MCIDAS (Multicilin), CCNO (Cyclin O), CCDC39&#xD;
      (Coiled-Coil Domain Containing 39) and CCDC40 (Coiled-Coil Domain Containing 40) and a severe&#xD;
      clinical course in particular a worse respiratory phenotype. There might be a less severe&#xD;
      phenotype in PCD sub-types due to mutations in genes encoding radial spoke components.&#xD;
&#xD;
      Currently a systematic review shows the high variation of spirometric indices in a great PCD&#xD;
      cohort. These findings underline the great necessity of detailed characterization of genotype&#xD;
      specific phenotypes with focus on important parameters such as lung function to better&#xD;
      understand the natural history of distinct PCD-variants with a view to improve individual&#xD;
      patient care by tailored treatment activity according to likely disease severity.&#xD;
&#xD;
      Aim of this study are:&#xD;
&#xD;
        -  Correlation between genotype and lung function of patients with genetically confirmed&#xD;
           PCD in an international cohort on a longitudinal basis&#xD;
&#xD;
        -  Determination of further parameters, such as body mass index (BMI), possibly associated&#xD;
           with lung function in genetically confirmed PCD patients&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  Patients with a genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene,&#xD;
           known to cause PCD) with typical clinical symptoms of PCD and at least one other method&#xD;
           confirming PCD-diagnosis&#xD;
&#xD;
        -  Children and adults diagnosed with PCD of all age groups and able to perform spirometry&#xD;
&#xD;
        -  Longitudinal datasets with measurements of lung function (FEV1 (forced expiratory volume&#xD;
           in 1 second), FVC (forced vital capacity), FEV1/FVC, FEF (forced expiratory flow) 25-75)&#xD;
           (with date and height at the performed measurement, respectively)&#xD;
&#xD;
        -  at least 3-4 different measurements in at least 2 years of follow up are expected - in&#xD;
           cases where this is not possible, sporadic data could also be provided&#xD;
&#xD;
        -  Delivery of datasets to the international PCD registry (NCT02419365) with all necessary&#xD;
           values within the anticipated time schedules&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genotype-Lungfunction Correlation</measure>
    <time_frame>up to 20 years (retrospective)</time_frame>
    <description>Lung function (FEV1, FVC, FEF) in correlation to the genetic make-up</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Ciliary Motility Disorders</condition>
  <condition>Primary Ciliary Dyskinesia</condition>
  <arm_group>
    <arm_group_label>Genetic diagnosis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic diagnosis</intervention_name>
    <description>No Intervention foreseen, but genetically confirmed diagnosis of PCD (bi-allelic mutations in a gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other method confirming PCD-diagnosis is needed</description>
    <arm_group_label>Genetic diagnosis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        PCD patients with proven bi-allelic mutations in a gene known to cause PCD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  Patients with a genetically confirmed diagnosis of PCD (bi-allelic mutations in a&#xD;
             gene, known to cause PCD) with typical clinical symptoms of PCD and at least one other&#xD;
             method confirming PCD-diagnosis&#xD;
&#xD;
          -  Children and adults diagnosed with PCD of all age groups and able to perform&#xD;
             spirometry&#xD;
&#xD;
          -  Longitudinal datasets with measurements of lung function (FEV1, FVC, FEV1/FVC,&#xD;
             FEF25-75) (with date and height at the performed measurement, respectively) at least&#xD;
             3-4 different measurements in at least 2 years of follow up are expected - in cases&#xD;
             where this is not possible, sporadic data could also be provided&#xD;
&#xD;
          -  Delivery of datasets to the international PCD registry (14) with all necessary values&#xD;
             within the anticipated time schedules&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heymut Omran, Prof., MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Muenster</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna Raidt, MD</last_name>
    <phone>+49 251 83 40003</phone>
    <email>Johanna.Raidt@ukmuenster.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simone Helms</last_name>
    <phone>+ 49 251 83 48358</phone>
    <email>Simone.Helms@ukmuenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Münster</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heymut Omran, Prof. Dr. MD</last_name>
      <phone>004925183</phone>
      <phone_ext>41097</phone_ext>
      <email>PCDregistry.eu@ukmuenster.de</email>
    </contact>
    <contact_backup>
      <last_name>Simone Helms</last_name>
      <phone>+4925183</phone>
      <phone_ext>48358</phone_ext>
      <email>Simone.Helms@ukmuenster.de</email>
    </contact_backup>
    <investigator>
      <last_name>Heymut Omran, Prof. Dr. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johanna Raidt, MD, Dr. med.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciliary Motility Disorders</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

